Alnorin
Latest Information Update: 19 Nov 2004
At a glance
- Originator Vector
- Class Antineoplastics
- Mechanism of Action Tumour necrosis factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Head and neck cancer
Most Recent Events
- 19 Nov 2004 Discontinued - Phase-I for Head and neck cancer in Russia (Intra-arterial)
- 07 Sep 2000 No-Development-Reported for Head and neck cancer in Russia (Intra-arterial)
- 29 Sep 1997 Phase-I clinical trials for Head and neck cancer in Russia (Intra-arterial)